Skip to main content
Figure 1 | Respiratory Research

Figure 1

From: The laminin β1-competing peptide YIGSR induces a hypercontractile, hypoproliferative airway smooth muscle phenotype in an animal model of allergic asthma

Figure 1

Increased ASM mass after repeated allergen challenge in vivo is inhibited by topical treatment with YIGSR. To assess the role of laminins in increased ASM mass in asthma, the effects of treatment with YIGSR were evaluated in a guinea pig model of chronic allergic asthma. (A) Treatment with YIGSR fully inhibited ovalbumin-induced increase in sm-MHC positive area in cartilaginous airways. (B) Changes in ASM mass were mainly dependent on changes in ASM cell number, only a small increase in cell size was observed for the YIGSR-treated, ovalbumin-challenged animals. (C) Increased pulmonary expression of the proliferative marker PCNA after repeated ovalbumin-challenges, was almost fully reversed by YIGSR. Representative blots of PCNA and β-actin are shown. No effects of YIGSR were shown in saline-challenged animals for any of the parameters. *P < 0.05, ***P < 0.001 compared to saline-treated, saline-challenged controls. ###P < 0.001 compared to saline-treated, ovalbumin-challenged controls. Data represent means ± SEM of 5-7 animals.

Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us